Insulin replacement therapy has been the mainstay of treatment for CFRD because it addresses both the protein catabolic state that results from insulin insufficiency, and the pro-inflammatory, pro-infectious state caused by hyperglycemia. This evidence concerns the gene INS and Hyperglycemia.